New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2013
09:03 EDTASTMAastrom announces first patients treated in ixCELL-DCM clinical study of ixmyelocel-T
Aastrom Biosciences announced that the first patients were treated in the ixCELL-DCM Phase 2b clinical trial. This study is evaluating the safety and efficacy of ixmyelocel-T compared to placebo in patients with advanced heart failure due to ischemic dilated cardiomyopathy. Aastrom has received U.S. orphan drug designation for the use of ixmyelocel-T in patients with DCM.
News For ASTM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ASTM

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use